Navigation Links
New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered
Date:8/17/2010

Cold Spring Harbor, NY -- One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.

A team led by Raffaella Sordella, Ph.D., an Assistant Professor at Cold Spring Harbor Laboratory (CSHL), today published results of a study that suggests new ways in which tumor cells develop resistance to one of the most successful targeted therapies, the small-molecule drug Tarceva (erlotinib). Since its approval by the U.S. Food and Drug Administration in 2004, Tarceva has produced dramatic, albeit impermanent, remissions in a subset of patients with notoriously difficult-to-treat cancers including non-small cell lung cancer (NSCLC) and pancreatic cancer.

Tarceva homes in on a specific area, or domain, of a very common cell-membrane receptor called EGFR, the epidermal growth-factor receptor. The drug has been shown to be effective in some NSCLC patients with specific oncogenic (cancer-promoting) mutations of EGFR. The drug molecule physically occupies a tiny pocket in the receptor structure--within an area called the tyrosine kinase domain, located just beneath the surface of the cell. This prevents the receptor from initiating a cascade of internal signals that can cause cellular growth to careen out of control, something like a switch stuck in the "on" position.

Over recent years Sordella and colleagues have focused on the question of how NSCLC tumor cells develop resistance to Tarceva. Specifically, they wanted to move beyond known explanations accounting for about half of the observed resistance. "Our colleagues in the field have already shown that secondary mutations of EGFR or amplification of a gene called c-MET are responsible for about 50% of cases of Tarceva resistance. We wanted to explain the other cases, in which the mechanism of resistance simply was not known."

Sordella's team, which was joined by investigators from Weill Cornell Medical College of Cornell University and the Boltzmann Institute for Cancer Research in Vienna, found what they regard as "compelling evidence" of other modes of resistance. One pertains to a population of NSCLC cells within untreated tumors that they found to be "intrinsically resistant" to Tarceva. These are cells--accounting for about 3% of the tumor samples studiedthat exhibit features suggestive of something scientists call EMT: the transition of normal epithelial cells to mesenchymal cells--cells with an increased metastatic potential.

This subpopulation of tumor cells were observed to secrete elevated amounts of TGF-β, a type of growth factor that plays a role in cell differentiation, development, and in regulation of the immune system. Up-regulation of TGF-β in these tumor cells resulted in increased secretion of a signaling molecule called IL-6, which among other things is also involved in immune responses. This subset of tumor cells with up-regulated TGF-β and increased IL-6 secretion was observed to resist treatment with Tarceva, independently of the EGFR pathway.

"This led us to the idea that inflammation might be one of the factors that could reduce a lung tumor cell's sensitivity to Tarceva," Sordella says. Since IL-6 and TGF-β are actively produced during the general inflammatory process, the team was led to explore whether inflammation mediated by non-cancer cells in the tumor microenvironment might also play a role in resistance to Tarceva. Using mouse models, the team was able to show precisely that.

Why IL-6 seems to be required for the survival of the cancer cells is not yet clear," Sordella notes. "We hypothesize that it plays a role in protecting cells from programmed cell-death, or apoptosis. We expect to investigate that possibility in future studies."


'/>"/>

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

Related biology news :

1. Corn researchers discover novel gene shut-off mechanisms
2. Mechanisms of cardiovascular disease and cancer give clues to new therapies
3. Neural mechanisms of value bias in the human visual cortex
4. I feel your pain: Neural mechanisms of empathy
5. DNA repair mechanisms relocate in response to stress
6. Disease Models & Mechanisms -- selected for indexing in Medline
7. Researcher garners major award from NIH for further exploration into the mechanisms of obesity
8. UT Southwestern researchers examine mechanisms that help cancer cells proliferate
9. Seeing how evolutionary mechanisms yield biological diversity
10. New research into the mechanisms of gene regulation
11. IUPUI researchers tackle protein mechanisms behind limb regeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... Dutch philosopher Koert van Mensvoort - founder of the Next Nature ... Eindhoven - has written a ,Letter to Humanity, in support of ... becoming a slave and victim to its own technology, but to employ technology ... ... Mensvoort – founder of the Next Nature Network and Fellow of ‘Next Nature’ ...
(Date:4/20/2017)... , April 20, 2017 For ... focuses on novel drug development and clinical research aimed at ... Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite ... ZIOP ). You can access our complimentary research reports ... ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments ... which is part of the Protein and Cell Analysis Education Webinar Series , ... this technology fits in current and future applications. , Many flow cytometers have ...
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... ... Halo Labs . The move comes after the company changed focus to ... market, our new brand and our new technology,” says CEO Robert Hart. Founders ...
Breaking Biology Technology: